Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
Stock Information for Aclaris Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.